PittsburghV1, France, Analysis, bibRecord, 000549

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Identifieur interne : 000549 ( France/Analysis ); précédent : 000548; suivant : 000550

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Auteurs : John M. Kirkwood [États-Unis] ; Lars Bastholt [Danemark] ; Caroline Robert [France] ; Jeff Sosman [États-Unis] ; James Larkin [Royaume-Uni] ; Peter Hersey [Australie] ; Mark Middleton [Royaume-Uni] ; Mireille Cantarini [Royaume-Uni] ; Victoria Zazulina [Royaume-Uni] ; Karin Kemsley [Royaume-Uni] ; Reinhard Dummer [Suisse]

Source :

Clinical cancer research [ 1078-0432 ] ; 2012.

RBID : Pascal:12-0187040

Descripteurs français

Pascal (Inist)
- Essai clinique phase II, Essai clinique, Randomisation, Inhibiteur, Etude comparative, Témozolomide, Homme, Malade, Stade avancé, Mélanome malin, Anticancéreux, Sélumétinib, Monothérapie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Advanced stage, Antineoplastic agent, Clinical trial, Comparative study, Human, Inhibitor, Malignant melanoma, Monotherapy, Patient, Phase II trial, Randomization, Selumetinib, Temozolomide.

Abstract

Purpose: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. Experimental Design: This phase II, open-label, multicenter, randomized, parallel-group study examined the effect of 100 mg oral selumetinib twice daily in 28-day cycles versus oral temozolomide (200 mg/m²/d for 5 days, then 23 days off-treatment). The primary endpoint was progression-free survival. Results: Two hundred patients were randomized. Progression-free survival did not differ significantly between selumetinib and temozolomide (median time to event 78 and 80 days, respectively; hazard ratio, 1.07; 80% confidence interval, 0.86-1.32). Objective response was observed in six (5.8%) patients receiving selumetinib and nine (9.4%) patients in the temozolomide group. Among patients with BRAF mutations, objective responses were similar between selumetinib and temozolomide groups (11.1% and 10.7%, respectively). However, five of the six selumetinib partial responders were BRAF mutated. Frequently reported adverse events with selumetinib were dermatitis acneiform (papular pustular rash; 59.6%), diarrhea (56.6%), nausea (50.5%), and peripheral edema (40.4%), whereas nausea (64.2%), constipation (47.4%), and vomiting (44.2%) were reported with temozolomide. Conclusions: No significant difference in progression-free survival was observed between patients with unresectable stage III/IV melanoma unselected for BRAF/NRAS mutations, who received therapy with selumetinib or temozolomide. Five of six patients with partial response to selumetinib had BRAF mutant tumors.

Affiliations:

Australie, Danemark, France, Royaume-Uni, Suisse, États-Unis
Angleterre, Grand Londres, Oxfordshire, Pennsylvanie, Tennessee
Londres, Oxford, Pittsburgh
Université de Pittsburgh

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 004410
to stream PascalFrancis, to step Curation: 000A95
to stream PascalFrancis, to step Checkpoint: 002C81
to stream Main, to step Merge: 008F67
to stream Main, to step Curation: 008989
to stream Main, to step Exploration: 008989
to stream France, to step Extraction: 000549

Links to Exploration step

Pascal:12-0187040

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma</title>
<author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Medicine and Dermatology, University of Pittsburgh</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Melanoma Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bastholt, Lars" sort="Bastholt, Lars" uniqKey="Bastholt L" first="Lars" last="Bastholt">Lars Bastholt</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Oncology, Odense University Hospital</s1>
<s2>Odense</s2>
<s3>DNK</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
<wicri:noRegion>Odense</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Medicine, Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sosman, Jeff" sort="Sosman, Jeff" uniqKey="Sosman J" first="Jeff" last="Sosman">Jeff Sosman</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Vanderbilt Ingram Cancer Center</s1>
<s2>Nashville, Tennessee</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Royal Marsden Hospital, Department of Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Newcastle Melanoma Unit</s1>
<s2>Newcastle, New South Wales</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Newcastle Melanoma Unit</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Middleton, Mark" sort="Middleton, Mark" uniqKey="Middleton M" first="Mark" last="Middleton">Mark Middleton</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>NIHR Biomedical Research Centre, Churchill Hospital</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cantarini, Mireille" sort="Cantarini, Mireille" uniqKey="Cantarini M" first="Mireille" last="Cantarini">Mireille Cantarini</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>AstraZeneca, Alderley Park</s1>
<s2>Macclesfield</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>AstraZeneca, Alderley Park</s1>
<s2>Macclesfield</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kemsley, Karin" sort="Kemsley, Karin" uniqKey="Kemsley K" first="Karin" last="Kemsley">Karin Kemsley</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>AstraZeneca, Alderley Park</s1>
<s2>Macclesfield</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Dermatology, Zurich University Hospital</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0187040</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0187040 INIST</idno>
<idno type="RBID">Pascal:12-0187040</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004410</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A95</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002C81</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002C81</idno>
<idno type="wicri:doubleKey">1078-0432:2012:Kirkwood J:phase:ii:open</idno>
<idno type="wicri:Area/Main/Merge">008F67</idno>
<idno type="wicri:Area/Main/Curation">008989</idno>
<idno type="wicri:Area/Main/Exploration">008989</idno>
<idno type="wicri:Area/France/Extraction">000549</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma</title>
<author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Medicine and Dermatology, University of Pittsburgh</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Melanoma Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bastholt, Lars" sort="Bastholt, Lars" uniqKey="Bastholt L" first="Lars" last="Bastholt">Lars Bastholt</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Oncology, Odense University Hospital</s1>
<s2>Odense</s2>
<s3>DNK</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Danemark</country>
<wicri:noRegion>Odense</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Medicine, Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sosman, Jeff" sort="Sosman, Jeff" uniqKey="Sosman J" first="Jeff" last="Sosman">Jeff Sosman</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Vanderbilt Ingram Cancer Center</s1>
<s2>Nashville, Tennessee</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Royal Marsden Hospital, Department of Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Newcastle Melanoma Unit</s1>
<s2>Newcastle, New South Wales</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Newcastle Melanoma Unit</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Middleton, Mark" sort="Middleton, Mark" uniqKey="Middleton M" first="Mark" last="Middleton">Mark Middleton</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>NIHR Biomedical Research Centre, Churchill Hospital</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cantarini, Mireille" sort="Cantarini, Mireille" uniqKey="Cantarini M" first="Mireille" last="Cantarini">Mireille Cantarini</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>AstraZeneca, Alderley Park</s1>
<s2>Macclesfield</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>AstraZeneca, Alderley Park</s1>
<s2>Macclesfield</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kemsley, Karin" sort="Kemsley, Karin" uniqKey="Kemsley K" first="Karin" last="Kemsley">Karin Kemsley</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>AstraZeneca, Alderley Park</s1>
<s2>Macclesfield</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Dermatology, Zurich University Hospital</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical cancer research</title>
<title level="j" type="abbreviated">Clin. cancer res.</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical cancer research</title>
<title level="j" type="abbreviated">Clin. cancer res.</title>
<idno type="ISSN">1078-0432</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antineoplastic agent</term>
<term>Clinical trial</term>
<term>Comparative study</term>
<term>Human</term>
<term>Inhibitor</term>
<term>Malignant melanoma</term>
<term>Monotherapy</term>
<term>Patient</term>
<term>Phase II trial</term>
<term>Randomization</term>
<term>Selumetinib</term>
<term>Temozolomide</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique phase II</term>
<term>Essai clinique</term>
<term>Randomisation</term>
<term>Inhibiteur</term>
<term>Etude comparative</term>
<term>Témozolomide</term>
<term>Homme</term>
<term>Malade</term>
<term>Stade avancé</term>
<term>Mélanome malin</term>
<term>Anticancéreux</term>
<term>Sélumétinib</term>
<term>Monothérapie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. Experimental Design: This phase II, open-label, multicenter, randomized, parallel-group study examined the effect of 100 mg oral selumetinib twice daily in 28-day cycles versus oral temozolomide (200 mg/m<sup>2</sup>
/d for 5 days, then 23 days off-treatment). The primary endpoint was progression-free survival. Results: Two hundred patients were randomized. Progression-free survival did not differ significantly between selumetinib and temozolomide (median time to event 78 and 80 days, respectively; hazard ratio, 1.07; 80% confidence interval, 0.86-1.32). Objective response was observed in six (5.8%) patients receiving selumetinib and nine (9.4%) patients in the temozolomide group. Among patients with BRAF mutations, objective responses were similar between selumetinib and temozolomide groups (11.1% and 10.7%, respectively). However, five of the six selumetinib partial responders were BRAF mutated. Frequently reported adverse events with selumetinib were dermatitis acneiform (papular pustular rash; 59.6%), diarrhea (56.6%), nausea (50.5%), and peripheral edema (40.4%), whereas nausea (64.2%), constipation (47.4%), and vomiting (44.2%) were reported with temozolomide. Conclusions: No significant difference in progression-free survival was observed between patients with unresectable stage III/IV melanoma unselected for BRAF/NRAS mutations, who received therapy with selumetinib or temozolomide. Five of six patients with partial response to selumetinib had BRAF mutant tumors.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Danemark</li>
<li>France</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Oxfordshire</li>
<li>Pennsylvanie</li>
<li>Tennessee</li>
</region>
<settlement><li>Londres</li>
<li>Oxford</li>
<li>Pittsburgh</li>
</settlement>
<orgName><li>Université de Pittsburgh</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
</region>
<name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
<name sortKey="Sosman, Jeff" sort="Sosman, Jeff" uniqKey="Sosman J" first="Jeff" last="Sosman">Jeff Sosman</name>
</country>
<country name="Danemark"><noRegion><name sortKey="Bastholt, Lars" sort="Bastholt, Lars" uniqKey="Bastholt L" first="Lars" last="Bastholt">Lars Bastholt</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name>
</noRegion>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name>
</region>
<name sortKey="Cantarini, Mireille" sort="Cantarini, Mireille" uniqKey="Cantarini M" first="Mireille" last="Cantarini">Mireille Cantarini</name>
<name sortKey="Kemsley, Karin" sort="Kemsley, Karin" uniqKey="Kemsley K" first="Karin" last="Kemsley">Karin Kemsley</name>
<name sortKey="Middleton, Mark" sort="Middleton, Mark" uniqKey="Middleton M" first="Mark" last="Middleton">Mark Middleton</name>
<name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name>
</country>
<country name="Australie"><noRegion><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000549 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000549 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:12-0187040
   |texte=   Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri